Dermira (NASDAQ:DERM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The brokerage currently has a $8.25 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price points to a potential upside of 11.34% from the stock’s current price.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
Several other equities analysts have also recently commented on the stock. ValuEngine cut shares of Dermira from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. Cantor Fitzgerald set a $20.00 target price on shares of Dermira and gave the company a “buy” rating in a research note on Friday, December 28th. BidaskClub cut shares of Dermira from a “buy” rating to a “hold” rating in a research note on Friday, December 28th. Guggenheim reissued a “buy” rating and set a $20.00 target price on shares of Dermira in a research note on Tuesday, November 20th. Finally, Mizuho restated a “hold” rating and set a $10.00 price objective on shares of Dermira in a research report on Tuesday, October 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $21.04.
Dermira (NASDAQ:DERM) last released its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($1.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.63) by $0.05. The firm had revenue of $0.72 million for the quarter, compared to analysts’ expectations of $0.80 million. Dermira had a negative net margin of 496.49% and a negative return on equity of 184.43%. Research analysts expect that Dermira will post -5.2 earnings per share for the current fiscal year.
In other news, Director Matthew K. Fust sold 4,000 shares of the firm’s stock in a transaction dated Friday, October 19th. The shares were sold at an average price of $13.75, for a total transaction of $55,000.00. Following the completion of the transaction, the director now owns 14,051 shares in the company, valued at approximately $193,201.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 14.80% of the company’s stock.
Large investors have recently bought and sold shares of the company. Voya Investment Management LLC boosted its holdings in shares of Dermira by 7.5% in the second quarter. Voya Investment Management LLC now owns 1,197,773 shares of the biopharmaceutical company’s stock worth $11,020,000 after buying an additional 83,064 shares during the period. Orbimed Advisors LLC acquired a new position in shares of Dermira in the second quarter worth about $9,491,000. Dimensional Fund Advisors LP boosted its holdings in shares of Dermira by 48.0% in the third quarter. Dimensional Fund Advisors LP now owns 920,605 shares of the biopharmaceutical company’s stock worth $10,034,000 after buying an additional 298,677 shares during the period. Sofinnova Ventures Inc boosted its holdings in shares of Dermira by 35.9% in the third quarter. Sofinnova Ventures Inc now owns 495,293 shares of the biopharmaceutical company’s stock worth $5,399,000 after buying an additional 130,953 shares during the period. Finally, Fosun International Ltd acquired a new position in shares of Dermira in the third quarter worth about $3,805,000. Institutional investors own 84.90% of the company’s stock.
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Featured Article: What Does Beta Mean In Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.